Related Experiment Video
Updated: Mar 22, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.5K
Increasing Patient Acceptance and Adherence Toward Insulin.
Matthew Riddle1, Anne Peters2, Martha Funnell3
1a Division of Endocrinology, Diabetes & Clinical Nutrition , Oregon Health & Science University , Portland , OR , USA.
Postgraduate Medicine
|April 26, 2016
Summary
Most type 2 diabetes mellitus (T2DM) patients require insulin for glycemic control. Healthcare practitioners were updated on initiating insulin therapy, overcoming barriers, and new insulin technologies to improve patient outcomes.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Type 2 diabetes mellitus (T2DM) is progressive, necessitating insulin therapy for sustained glycemic control in most patients.
- Effective glycemic management prevents hyperglycemia, stabilizes plasma glucose (PG), and delays diabetes complications, preserving quality of life.
- Despite guidelines, patient and health system barriers impede timely insulin initiation.
Purpose of the Study:
- To enhance healthcare practitioners' (HCPs) confidence in individualizing T2DM therapy.
- To review evidence on optimal timing for insulin initiation in T2DM.
- To address strategies for overcoming barriers to insulin therapy and discuss current/emerging insulin technologies.
Main Methods:
- Review of clinical evidence and treatment recommendations for T2DM.
- Discussion of patient and provider-related barriers to insulin initiation.
- Evaluation of safety and efficacy data for insulin therapies and delivery systems.
Main Results:
- HCPs received updated information on insulin initiation criteria and evidence-based strategies.
- Methods for overcoming common barriers to insulin adoption were presented.
- Current and novel insulin formulations and delivery devices were reviewed for T2DM management.
Conclusions:
- Optimizing insulin therapy in T2DM requires addressing barriers and utilizing advanced treatment options.
- Enhanced HCP knowledge supports improved patient outcomes and quality of life.
- Individualized insulin strategies are crucial for managing progressive T2DM effectively.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
1.1K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.1K
01:15Diabetes: Management and Pharmacotherapy
1.4K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.4K
01:27Insulin Formulations: Types and Delivery
1.1K
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
1.1K
01:22Diabetes Mellitus: Overview and Type I Subtype
5.9K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.9K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
909
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
909
01:22Diabetes Mellitus: Type 2 and Gestational
5.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.4K